We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 8.00 | 0.57% | 1,408.00 | 1,403.00 | 1,414.00 | 1,426.00 | 1,365.00 | 1,400.00 | 660,233 | 16:35:05 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1.09B | 2M | 0.0148 | 952.03 | 1.91B |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
Indivior PLC (INDV.LN) said Monday that a U.S. court ruled that Dr. Reddy's Laboratories Ltd. (500124.BY) and Alvogen Inc. (AVGN.XX) had not infringed on a patent for its Suboxone film anti-opioid addiction medication.
The two companies brought generic treatments to market for opioid addiction in February. The court decision confirms that these products aren't in violation of Indivior's patented product.
The U.S. court did rule against a third rival, Actavis Laboratories UT, Inc., which is barred from selling its product until the patent expiry in 2024.
Indivior shares at 1351 GMT were down 2.55 pence, or 5.80%, to 43.22 pence.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
July 15, 2019 10:18 ET (14:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Indivior Chart |
1 Month Indivior Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
